Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Equity Average (2016 - 2025)

Historic Equity Average for Editas Medicine (EDIT) over the last 10 years, with Q3 2025 value amounting to $16.3 million.

  • Editas Medicine's Equity Average fell 9199.25% to $16.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.3 million, marking a year-over-year decrease of 9199.25%. This contributed to the annual value of $241.7 million for FY2024, which is 3189.82% down from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Equity Average is $16.3 million, which was down 9199.25% from $40.8 million recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Equity Average registered a high of $625.7 million during Q2 2021, and its lowest value of $16.3 million during Q3 2025.
  • For the 5-year period, Editas Medicine's Equity Average averaged around $352.3 million, with its median value being $358.7 million (2023).
  • As far as peak fluctuations go, Editas Medicine's Equity Average surged by 10756.01% in 2021, and later tumbled by 9199.25% in 2025.
  • Editas Medicine's Equity Average (Quarter) stood at $570.2 million in 2021, then tumbled by 32.01% to $387.7 million in 2022, then decreased by 8.49% to $354.8 million in 2023, then tumbled by 56.32% to $155.0 million in 2024, then plummeted by 89.47% to $16.3 million in 2025.
  • Its last three reported values are $16.3 million in Q3 2025, $40.8 million for Q2 2025, and $98.3 million during Q1 2025.